RE: Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction

被引：1
|
作者：
Cristino, Joaquim [1 ]
Tang, Immanuel [2 ]
Ng, Caroline [2 ]
Tan, Jonathan [2 ]
Trueman, David [3 ]
Lee, Declan [4 ]
机构：
[1] Novartis Pharmaceut, Basel, Switzerland
[2] Novartis Pharmaceut, Singapore, Singapore
[3] SourceHEOR Consultancy, London, England
[4] Novartis Pharmaceut, Novartis Global Serv Ctr, Vista Bldg,Elm Pk Business Campus,Merrion Rd, Dublin, Ireland
来源：
JOURNAL OF MEDICAL ECONOMICS | 2018年 / 21卷 / 12期
关键词：
MORTALITY;
D O I：
10.1080/13696998.2018.1503597
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：1145 / 1147
页数：3
相关论文
共 50 条
  • [1] Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction
    Liang, Lin
    Wu, David Bin-Chia
    Aziz, Mohamed Ismail Abdul
    Wong, Raymond
    Sim, David
    Leong, Kui Toh Gerard
    Wei, Yong Quek
    Tan, Doreen
    Ng, Kwong
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (02) : 174 - 181
  • [2] Reply: Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction
    Liang, Lin
    Wu, David Bin-Chia
    Aziz, Mohamed Ismail Abdul
    Wong, Raymond
    Sim, David
    Leong, Kui Toh Gerard
    Wei, Yong Quek
    Tan, Doreen
    Ng, Kwong
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (12) : 1148 - 1149
  • [3] Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction
    Gaziano, Thomas A.
    Fonarow, Gregg C.
    Claggett, Brian
    Chan, Wing W.
    Deschaseaux-Voinet, Celine
    Turner, Stuart J.
    Rouleau, Jean L.
    Zile, Michael R.
    McMurray, John J. V.
    Solomon, Scott D.
    [J]. JAMA CARDIOLOGY, 2016, 1 (06) : 666 - 672
  • [4] Cost-Effectiveness of Sacubitril-Valsartan in Patients With Heart Failure With Reduced Ejection Fraction
    Sandhu, Alexander T.
    Ollendorf, Daniel A.
    Chapman, Richard H.
    Pearson, Steven D.
    Heidenreich, Paul A.
    [J]. ANNALS OF INTERNAL MEDICINE, 2016, 165 (10) : 681 - +
  • [5] COST-EFFECTIVENESS OF DAPAGLIFLOZIN VERSUS SACUBITRIL/VALSARTAN FOR THE TREATMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION
    McEwan, P.
    Darlington, O.
    Bergenheim, K.
    Qin, L.
    [J]. VALUE IN HEALTH, 2020, 23 : S494 - S494
  • [6] Cost-Effectiveness Analysis of Sacubitril-Valsartan Compared with Enalapril in Patients with Heart Failure with Reduced Ejection Fraction in Thailand
    Krittayaphong, Rungroj
    Permsuwan, Unchalee
    [J]. AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2018, 18 (05) : 405 - 413
  • [7] COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN HEART FAILURE WITH REDUCED EJECTION FRACTION IN SWEDEN
    Costa-Scharplatz, M.
    Lang, A.
    McMurray, J. J.
    Woodcock, F.
    Haroun, R.
    Johansson, D.
    Lund, L. H.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A650 - A651
  • [8] Cost-Effectiveness Analysis of Sacubitril-Valsartan Compared with Enalapril in Patients with Heart Failure with Reduced Ejection Fraction in Thailand
    Rungroj Krittayaphong
    Unchalee Permsuwan
    [J]. American Journal of Cardiovascular Drugs, 2018, 18 : 405 - 413
  • [9] Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction
    McMurray, John J. V.
    Trueman, David
    Hancock, Elizabeth
    Cowie, Martin R.
    Briggs, Andrew
    Taylor, Matthew
    Mumby-Croft, Juliet
    Woodcock, Fionn
    Lacey, Michael
    Haroun, Rola
    Deschaseaux, Celine
    [J]. HEART, 2018, 104 (12) : 1006 - 1013
  • [10] The cost-effectiveness of sacubitril/valsartan in chronic heart failure with reduced ejection fraction
    Mcmurray, J. J. V.
    Cowie, M. R.
    Briggs, A.
    Taylor, M.
    Hancock, E.
    Trueman, D. David
    Haroun, R.
    Deschaseaux, C.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2016, 18 : 276 - 276
12345